Ludocare is a technology company.
Ludocare has raised $4.0M across 1 funding round.
Ludocare has raised $4.0M in total across 1 funding round.
Ludocare has raised $4.0M in total across 1 funding round.
Ludocare's investors include Karista, Seroba Life Sciences, Soffinova Partners.
Ludocare is a Lyon-based French digital health company founded in 2017, specializing in pediatric Digital Therapeutics (DTx) for children with chronic illnesses, primarily persistent asthma.[1][2][3] It develops JOE, a connected medical device and interactive robot that serves children aged 3-11 and their families, solving key challenges like treatment non-adherence, improper inhaler use, and lack of autonomy through gamified education, real-time guidance, and data sharing with parents and doctors.[1][2][3] JOE is CE-marked as a Class 1 medical device, available by prescription, and has seen real-world adoption: over 750 children used it in a 2023-2024 French program involving 150 physicians, demonstrating strong growth momentum with grants like i-Lab (2019) and i-Nov (2024), plus a €4.2 million funding round.[1][2][3]
Ludocare emerged in Lyon, France, in 2017, driven by the need to address poor treatment compliance in pediatric chronic diseases, starting with asthma—the leading chronic condition in children.[1][2][3] Founders tapped into expertise at the intersection of digital health, pediatrics, and behavioral science, creating JOE as a "connected medical companion" robot that guides kids step-by-step during medication, using animations, rewards, and algorithms for personalization while sharing data via a parent app.[3] Early traction came via the 2019 i-Lab grant, funding JOE's first medical device version and an observational study validating its value; by 2024, i-Nov support accelerated scaling with eco-designed hardware and preventive features integrating environmental data.[1] A €4.2 million raise from investors like Karista and Bpifrance fueled clinical studies, prescription strategies, and team growth.[3]
Ludocare rides the explosive Digital Therapeutics wave (global CAGR +75%), merging AI, connected devices, and behavioral science to tackle public health priorities: early prevention, cost reduction, and healthcare sovereignty in pediatrics.[2][3] Timing aligns with Europe's maturing DTx regulations (e.g., CE marking) and post-pandemic demand for home-based chronic care, especially as pediatric asthma affects millions with high non-adherence rates (50%+).[1][3] Favorable forces include grants from French innovation bodies (i-Lab, i-Nov) and investor interest in scalable healthtech; Ludocare influences the ecosystem by proving DTx viability in kids, paving for platforms expandable to other diseases and inspiring family-centric models amid rising chronic illness burdens.[1][2][3]
Ludocare is primed for expansion with its €4.2M funding enabling clinical trials, international prescriptions, and team scaling—next steps likely include JOE's preventive upgrades and multi-disease extensions amid DTx market growth.[3] Trends like AI personalization, telehealth integration, and eco-healthtech will propel it, potentially evolving from asthma specialist to pediatric chronic care leader influencing global standards. This positions Ludocare to transform young lives, echoing its mission to rewrite chronic illness trajectories from the start.[2]
Ludocare has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in July 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2022 | $4.0M Seed | Karista, Seroba Life Sciences, Soffinova Partners |